A new strategy for metabolic stabilization of motilin using the C-terminal part of ghrelin |
| |
Authors: | Morozumi Naomi Sato Seiji Yoshida Sayaka Yamaki Akira Furuya Mayumi Inomata Norio Ohnuma Norio Minamitake Yoshiharu Ohsuye Kazuhiro Kangawa Kenji |
| |
Affiliation: | Faculty of Pharmacology I, Asubio Pharma Co, Ltd, 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan. morozumi.naomi.dg@asubio.co.jp |
| |
Abstract: | Ghrelin consists of 28 amino acid residues with an octanoyl modification at the third serine residue. Recently we have found that the C-terminal part of ghrelin protects the ester bond of 3-octanoyled serine from plasma esterases and plays the essential role to prolong the plasma half-life and to show its biological activity in vivo. In the present study, we researched whether the C-terminal part of ghrelin has a potential to prolong the plasma half-life of motilin, by comparing the pharmacokinetics of various chimeric peptides of ghrelin and motilin. Motilin is another gastro-intestinal peptide hormone related with ghrelin structurally, binding to the same family of G protein-coupled receptors. Chimeric peptides were designed to be composed of motilin(1-12) fragment, the active core binding to the motilin receptor, GPR38, and C-terminal part of ghrelin. The modification of motilin(1-12) fragment by C-terminal part of ghrelin hardly influenced its agonist activity to GPR38 and almost all these chimeric peptides showed more than two times longer plasma half-lives than motilin in rats. From the relationship between structures of chimeric peptides and their corresponding plasma half-lives, the mid-region of ghrelin rich in basic amino acids ((15)RKESKK(20)) was considered to be the most important in prolonging the plasma half-life of motilin. The deletion of these fragments or replacement of 17th glutamic acid with a neutral amino acid resulted in short plasma half-lives. In conclusion, our data suggested that the C-terminal part of ghrelin has a potential to improve the biokinetics of motilin probably by a metabolic stabilizing effect. |
| |
Keywords: | PK, pharmacokinetic ip, intra-peritoneal iv, intravenous RIA, radio-immuno assay GPR38, G protein-coupled receptor 38 GHS-R1a, growth hormone secretagogue receptor 1a GH, growth hormone [Ca2+]i, intracellular calcium concentrations T1/2, terminal half-life in plasma EC50, half maximal effective concentration SD, standard deviation |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|